Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis
Objectives This exploratory analysis investigated the potential use of the multibiomarker disease activity (MBDA) score to support biosimilarity assessments using data from two randomised controlled trials (RCTs) of biosimilar infliximab (IFX-qbtx) and biosimilar adalimumab (ADL-afzb) versus EU-sour...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2022-11-01
|
| Edice: | RMD Open |
| On-line přístup: | https://rmdopen.bmj.com/content/8/2/e002423.full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|